MedTrace Logo

Reliability of Respiratory Variability of Maximal Aortic Blood Flow Velocity Obtained by Ultrasonography-doppler in Patients Followed Up with a Diagnosis of Shock in Intensive Care Unit for Evaluating Fluid Responsiveness in Patients

NCT06845280 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-02-25

No results posted yet for this study

Summary

Original value: Shock is an important cause of mortality in intensive care units (ICU). Determining whether shock patients will benefit from (intravenous) IV fluid therapy is possible by fluid responsiveness parameters/tests. More than half of the patients being monitored for shock in the ICU are not fluid responders. Especially in patients who do not have the desired response despite appropriate shock treatment for the first 6 hours, continuing IV bolus fluid treatments without performing fluid responsiveness tests may cause an increase in mortality due to hypervolemia and organ edema. Today, these tests can be measured with transpulmonary thermodilution (TPTD) devices. Calibration, installation and evaluation of the device requires expert personnel and its use can cause a significant increase in intensive care workload. Instead of this minimal invasive approach, the respiratory variability of maximal aortic blood flow rate (ΔVaortmax), which can be obtained non-invasively with the use of bedside ultrasonography (USG), can be used as a fluid responsiveness parameter. There is no study on the value of this parameter in adult intensive care patients. Revealing the importance of this parameter as a fluid responsiveness parameter may pave the way for ultrasonography devices, which are already in use with other indications, to be used as an important advanced hemodynamic monitoring tool. For this purpose, this prospective observational study was planned.

Method: This study was planned to be conducted on non-pregnant shock patients who are greater than 18 years and who were admitted to Medical ICU of Ankara University Faculty of Medicine, Department of Internal Medicine Division of Intensive Care. It was planned to establish the TPTD system, which is a standard practice in patients whose shock symptoms did not improve and whose lactate level did not decrease despite appropriate fluid, vasopressor and standard intensive care applications for the first 6 hours, and to compare the fluid responsiveness parameters obtained from this TPTD system with the ΔVaortmax obtained by bedside USG. Within the scope of a 6-12 month study period, it is planned to perform advanced hemodynamic monitoring with TPTD in 60 patients and to compare the obtained measurements with ΔVaortmax measurements with bedside USG. In order to carry out the project, a TPTD device and its thermodilution catheters as well as a standard ultrasonography device with an echocardiography system are needed.

Management: Patients who are admitted with shock to our ICU and who develop shock state during their admission will be evaluated for eligibility for the study. A TPTD system will be installed in patients eligible for the study, and a bedside USG will be performed simultaneously and fluid responsiveness and other clinical and hemodynamic data will be recorded. Data will be analyzed to evaluate whether ΔVaortmax, is a good fluid responsiveness parameter for adult shock patients and to determine a cutoff value to assign volume responsive patients.

Widespread effect: With this project, USG/echocardiography devices, which are already commonly used in ICU's for various purposes, will find a new use as advanced hemodynamic monitoring tools to determine fluid responsiveness during shock states, without incurring additional risks to patiens with minimal additional costs. Importantly, this method may reduce the need for some minimally invasive methods such as transpulmonary thermodilution. The results of our project will be disseminated through oral presentations and articles.

Conditions

  • Shock

Sponsors & Collaborators

  • The Scientific and Technological Research Council of Turkey

    collaborator OTHER

  • Ankara University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-28
Primary Completion
2026-01-31
Completion
2026-04-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06845280 on ClinicalTrials.gov